Ask VialBase
growth · hormone

CJC-1295

Also known as: CJC-1295 DAC, CJC-1295 no DAC, Mod GRF 1-29, Modified GRF(1-29), Tetrasubstituted GRF(1-29)
FDA: Not FDA-approved WADA: Prohibited
Last updated · 2026-06-19

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) — the endogenous 44-amino-acid hypothalamic peptide that signals the anterior pituitary to release growth hormone. CJC-1295 uses four amino acid substitutions to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), dramatically extending its half-life compared to native GHRH. Two forms exist: - CJC-1295 no DAC (Mod GRF 1-29) — Short-acting (~30 min half-life), produces discrete GH pulses. Preferred for mimicking natural GH physiology. - CJC-1295 with DAC — Drug Affinity Complex covalently binds to albumin, extending half-life to ~8 days. Produces sustained GH elevation rather than pulsatile release. Almost always

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 3,367.97 Da
Half-life ~30 min no
CAS number 446262-90-4
Route Subcutaneous
Where to buy CJC-1295 →BioLongevity Labs · save 15% code VIALBASE
⚠️ CJC-1295 side effects — common, serious & how to reduce them →
02

Dosing

DOSE RANGE 100–300 mcg
FREQUENCY 1-3x daily (no DAC) / 2x weekly (DAC)
CYCLE LENGTH 8-12 weeks

Usually stacked with Ipamorelin for synergistic GH release. Best dosed before bed or post-workout.

03

Mechanism

Growth hormone releasing hormone (GHRH) analog — binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH synthesis and pulsatile release

04

Research summary

Study Type Year Key Finding
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Narrative review 2026 CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension in mice with glucocorticoid-induced muscle loss
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Review 2026 Growth hormone secretagogues, including ipamorelin, CJC-1295, tesamorelin, sermorelin and AOD-9604, are described as activating IGF-1 signaling and satellite cell repair
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review Critical review 2026 CJC-1295 identified among most popular GH-releasing peptides in sport
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog clinical trial (single dose, before vs after) 2006 GH pulsatility was preserved 1 week after a single CJC-1295 injection; pulse frequency and magnitude were unchanged
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults clinical trial 2006 Single dose of CJC-1295 DAC elevated GH and IGF-1 for 6-14 days
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men clinical trial 2009 GHRH-GHRP synergy was lower with older age and more abdominal visceral fat (both P < 0.001)
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse animal study (mouse) 2006 Daily CJC-1295 (2 µg) for 5 weeks gave GHRH knockout mice normal body weight and length
05

Stacking & interactions

GHRH + GHRP synergy for amplified GH pulse

GH-mediated recovery amplification for injury healing

Comprehensive healing — GH elevation + targeted tissue repair

Stacks containing CJC-1295

Marquee

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin

Anabolic Growth

CJC-1295 (w/ DAC) + Ipamorelin + IGF-1 LR3

Bone Density Builder

CJC-1295 + Ipamorelin + GHK-Cu

GH-Boost Metabolic

CJC-1295 (w/ DAC) + Ipamorelin + AOD-9604

HPTA Reboot

Kisspeptin-10 + Gonadotropin + CJC-1295 + Ipamorelin

Spartan

CJC-1295 + Ipamorelin + IGF-1 LR3 + BPC-157

T-Boost & GH Sync

Kisspeptin-10 + CJC-1295 + Ipamorelin + IGF-1 LR3 (low dose)

28-day resets featuring CJC-1295

06

Sourcing

Current prices

Updated today

2mg

5mg

10mg

Only vendor stocking this size on the VialBase roster.

Size unspecified

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code vialbase15 at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 10% with code aewpzbzd at checkout

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • IGF-1
  • Fasting Glucose
  • Fasting Insulin
  • HbA1c
  • CMP
  • CBC
  • Lipid Panel
DURING CYCLE
  • IGF-1
  • Fasting Glucose
  • Fasting Insulin
POST-CYCLE
  • IGF-1
  • Fasting Glucose
  • Lipid Panel
Safety & Regulatory Status
FDA STATUS Not FDA-approved. Not on the 503A bulks list and in none of FDA's interim Category 1, 2, or 3 lists — there is no lawful 503A or 503B compounding route.
WADA STATUS Prohibited (S2 — peptide hormones, growth factors, and related substances)

Regulatory status for CJC-1295 may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). Four amino-acid substitutions make it resist DPP-IV degradation, extending its half-life versus native GHRH. It signals the anterior pituitary to release growth hormone in physiological pulses. Two forms exist: "no DAC" (Mod GRF 1-29, short-acting) and "with DAC" (albumin-bound, ~8-day half-life). It is most often paired with Ipamorelin.
How does CJC-1295 work?
CJC-1295 binds GHRH receptors on pituitary somatotroph cells, activating a cAMP/protein-kinase-A cascade that triggers growth hormone synthesis and release. The released GH stimulates the liver to produce IGF-1, the main mediator of GH's effects on muscle, bone, and connective tissue. Because it prompts the body's own pulsatile GH output, it differs from injecting synthetic GH directly.
What is the difference between CJC-1295 with DAC and no DAC?
"No DAC" (Mod GRF 1-29) is short-acting, with about a 30-minute half-life, producing discrete GH pulses that mimic natural physiology; it requires multiple daily doses. "With DAC" uses a Drug Affinity Complex that binds albumin, extending the half-life to roughly 8 days for sustained GH elevation and once- or twice-weekly dosing. Many practitioners prefer no DAC to preserve pulsatility.
How is CJC-1295 dosed?
Commonly cited research protocols use 100–300 mcg of the no-DAC form, one to three times daily (often before bed), in 8–12 week cycles; the DAC form is dosed roughly 1–2 mg once or twice weekly. It is injected subcutaneously on an empty stomach and frequently combined with Ipamorelin. These figures reflect research protocols, not medical advice — consult a clinician.
What does the research on CJC-1295 show?
The evidence tier is early-phase human pharmacokinetics, not large outcome trials (about 28 PubMed entries). A randomized study in healthy adults found CJC-1295 with DAC produced prolonged growth hormone and IGF-1 elevation lasting several days after a single subcutaneous dose (Teichman et al., J Clin Endocrinol Metab 2006, PMID 16352683). No large trials confirm body-composition or anti-aging outcomes.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved. It is also not on the 503A bulks list — the list of bulk drug substances compounding pharmacies may use — and it appears in none of FDA's interim Category 1, 2, or 3 lists, so there is no lawful compounding route through a 503A pharmacy or a 503B outsourcing facility. WADA prohibits it under category S2 (peptide hormones and growth factors), so competitive athletes cannot use it. It is not a DEA-controlled substance.
What are the side effects of CJC-1295?
Reported side effects include injection-site reactions, mild water retention, tingling or numbness in the extremities, transient flushing, increased hunger, and fatigue during adaptation. Carpal-tunnel-type symptoms are associated with sustained GH/IGF-1 elevation and are more common with the DAC form. It is contraindicated in active cancer, since IGF-1 can promote tumor growth, and in pregnancy.

References

  1. Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine (2026). PMID: 41476424
  2. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews (2026). PMID: 41490200
  3. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. Journal of Sports Medicine and Physical Fitness (2026). PMID: 41880199
  4. Ionescu, M., Frohman, L.A.. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism (2006). PMID: 17018654
  5. Teichman, S.L., Neale, A., Lawrence, B. et al.. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology and Metabolism (2006). PMID: 16352683
  6. Veldhuis, J.D., Bowers, C.Y.. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. American Journal of Physiology - Endocrinology and Metabolism (2009). PMID: 19240251
  7. Alba, M., Fintini, D., Sagazio, A. et al.. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism (2006). PMID: 16822960